This study investigates the synthesis and characterization of cationic porphyrins, namely P3AmM, PAm3M, and c-P2Am2M, and their zinc(II)-complexes, P3AmZM, PAm3ZM, and c-P2Am2ZM. These compounds were developed by strategically methylating primary amino groups in precursor porphyrins to overcome steric hindrances associated with repetitive amine alkylation. Under photodynamic therapy (PDT) conditions, these porphyrins showed significant suppression of HIV-1 synthesis and infection, along with antibacterial properties against drug-resistant Escherichia coli and Staphylococcus aureus isolates. The bacterial growth dynamics indicated restrained proliferation and reduced biofilm production in the presence of the porphyrins over five days, underscoring their efficacy as antibacterial agents. Particularly, P3AmZM, PAm3ZM, c-P2Am2ZM, c-P2Am2ZM, and PAm3M exhibited heightened antibacterial activity against both strains, with Staphylococcus aureus showing greater susceptibility. Disc diffusion assays highlighted the superior antibacterial efficacy of compounds c-P2Am2M and c-P2Am2ZM, particularly against Staphylococcus aureus. Computational molecular docking simulations revealed enhanced binding energy and interaction profiles of the lead compounds, c-P2Am2M and c-P2Am2ZM, with various HIV targets. These findings suggest these compounds deserve recognition as prospective synergistic anti-HIV agents with potent antibiotic properties under PDT conditions.